EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands

Simon van der Schans, Rimma Velikanova, Diana Weidlich, Ruth Howells, Anish Patel, Matthias Bischof, Maarten J Postma, Cornelis Boersma

The European Journal of Health Economics · 2025

DOI: 10.1007/s10198-024-01754-3 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The European Journal of Health Economics, 2025. Verfasst von Simon van der Schans und 7 weiteren Autor:innen. Beteiligte Einrichtung: Health-Ecore, Zeist, The Netherlands. S.van.der.schans@umcg.nl. Hauptthemen laut MEDLINE: Oligonucleotides, Spinal Muscular Atrophies of Childhood, Biological Products. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Gene Therapies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligonucleotidesSpinal Muscular Atrophies of ChildhoodBiological ProductsHumansNetherlandsMaleFemaleInfantChild, PreschoolCost-Benefit AnalysisChildRecombinant Fusion Proteins

Stichwörter der Autor:innen

Cost comparison analysisGene therapyNusinersenOnasemnogene abeparvovecSpinal muscular atrophyThe Netherlands

Substanzen

nusinersenOligonucleotidesZolgensmaBiological ProductsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Health-Ecore, Zeist, The Netherlands. S.van.der.schans@umcg.nl.
  • Unit of Global Health, Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, 9173 GZ, The Netherlands. S.van.der.schans@umcg.nl.
  • Unit of Global Health, Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, 9173 GZ, The Netherlands.
  • Asc Academics, Groningen, The Netherlands.
  • Clarivate, Munich, Germany.
  • Clarivate, Manchester, UK.

Förderung

  • Novartis Gene Therapies

Zitieren

APA

van der Schans, S., Velikanova, R., Weidlich, D., Howells, R., Patel, A., Bischof, M., Postma, M. J., & Boersma, C. (2025). Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands. The European Journal of Health Economics. https://doi.org/10.1007/s10198-024-01754-3

Vancouver

van der Schans S, Velikanova R, Weidlich D, Howells R, Patel A, Bischof M, et al. Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands. The European Journal of Health Economics. 2025. doi:10.1007/s10198-024-01754-3

BibTeX
@article{vanderSchans2025,
  author = {van der Schans, Simon and Velikanova, Rimma and Weidlich, Diana and Howells, Ruth and Patel, Anish and Bischof, Matthias and Postma, Maarten J and Boersma, Cornelis},
  title = {Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands},
  journal = {The European Journal of Health Economics},
  year = {2025},
  doi = {10.1007/s10198-024-01754-3}
}
Kostenlos starten →